NFA
OREX

Nationwide Fund Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Nationwide Fund Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,999
Closed -$39K – 3418
2016
Q1 		$39K Buy
6,999
+344
+5% +$4.47K ﹤0.01% 3030
2015
Q4 		$114K Hold
6,655
– – ﹤0.01% 2797
2015
Q3 		$140K Hold
6,655
– – ﹤0.01% 2757
2015
Q2 		$329K Sell
6,655
-2,332
-26% -$139K ﹤0.01% 2469
2015
Q1 		$704K Sell
8,987
-326
-4% -$20.2K ﹤0.01% 2079
2014
Q4 		$564K Sell
9,313
-3,616
-28% -$182K ﹤0.01% 2114
2014
Q3 		$551K Buy
12,929
+501
+4% +$26.9K ﹤0.01% 2158
2014
Q2 		$768K Buy
12,428
+777
+7% +$45.2K ﹤0.01% 2031
2014
Q1 		$757K Buy
11,651
+1,831
+19% +$124K ﹤0.01% 1869
2013
Q4 		$553K Buy
9,820
+2,277
+30% +$128K ﹤0.01% 2198
2013
Q3 		$463K Sell
7,543
-2,851
-27% -$193K ﹤0.01% 2263
2013
Q2 		$608K Buy
+10,394
New +$639K ﹤0.01% 1932

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nationwide Fund Advisors's OREX Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 6,999 shares — an estimated $39K sold.

Nationwide Fund Advisors first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $768K in Q2 2014. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Nationwide Fund Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Nationwide Fund Advisors sold 6,999 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $39K.
  • Nationwide Fund Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • Nationwide Fund Advisors's Orexigen Therapeutics, Inc. position peaked at $768K in Q2 2014.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.